Evidence map›Paper›PMID 36925028›Full record

ArticleMitochondrion2023

HIV-1 gp120 protein promotes HAND through the calcineurin pathway activation.

Jenny Shrestha, Maryline Santerre, Charles N Allen, Sterling P Arjona, Robert Hooper, Ruma Mukerjee, Marcus Kaul, Natalia Shcherbik, Jonathan Soboloff, Bassel E Sawaya

Open access · greenAbstract read
In one paragraph

Article in Mitochondrion, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jenny ShresthaMolecular Studies of Neurodegenerative Diseases Lab; FELS Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine - Temple University Philadelphia, PA 19140, USA. Electronic address: jenny.shrestha@bms.com.
Maryline SanterreMolecular Studies of Neurodegenerative Diseases Lab; FELS Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine - Temple University Philadelphia, PA 19140, USA.
Charles N AllenMolecular Studies of Neurodegenerative Diseases Lab; FELS Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine - Temple University Philadelphia, PA 19140, USA.
Sterling P ArjonaMolecular Studies of Neurodegenerative Diseases Lab; FELS Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine - Temple University Philadelphia, PA 19140, USA.
Robert HooperFELS Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine - Temple University Philadelphia, PA 19140, USA.
Ruma MukerjeeMolecular Studies of Neurodegenerative Diseases Lab; FELS Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine - Temple University Philadelphia, PA 19140, USA.
Marcus KaulInfectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA; Department of Psychiatry, UCSD, San Diego, CA, USA; Division of Biomedical Sciences, School of Medicine, UCR, Riverside, CA, USA.
Natalia ShcherbikDepartment for Cell Biology and Neuroscience, School of Osteopathic Medicine, Rowan University, 2 Medical Center Drive, Stratford, NJ 08084, USA.
Jonathan SoboloffFELS Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine - Temple University Philadelphia, PA 19140, USA; Department of Cancer and Cellular Biology, Lewis Katz School of Medicine - Temple University Philadelphia, PA 19140, USA.
Bassel E SawayaMolecular Studies of Neurodegenerative Diseases Lab; FELS Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine - Temple University Philadelphia, PA 19140, USA; Department of Cancer and Cellular Biology, Lewis Katz School of Medicine - Temple University Philadelphia, PA 19140, USA. Electronic address: sawaya@temple.edu.
Temple University · USRowan University · USUniversity of California, Riverside · US

Funding

Translational Methamphetamine AIDS Research Center (TMARC)P50DA026306 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GRANT, IGOR · 2009 to 2018
$33.9M
Neuroprotection by IFN-beta in AIDSR01MH087332 · NIMH · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI KAUL, MARCUS · 2010 to 2019
$5.2M
Lipocalin-2 in HIV-Associated Neuronal InjuryR01MH104131 · NIMH · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI KAUL, MARCUS · 2015 to 2019
$2.2M
Cysteinyl Leukotrienes in HIV Brain InjuryR01MH105330 · NIMH · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI KAUL, MARCUS · 2015 to 2019
$2.0M
Defining STIM1 function at the Immunological SynapseR01AI152506 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI SOBOLOFF, JONATHAN A · 2020 to 2024
$2.0M
PGC-1alpha and Reelin: new players in HAND progression.R01AG054411 · NIA · TEMPLE UNIV OF THE COMMONWEALTH · PI SAWAYA, BASSEL E · 2017 to 2021
$2.0M
Involvement of HIV-1 Vpr in neuronal degeneration.R01NS076402 · NINDS · TEMPLE UNIV OF THE COMMONWEALTH · PI SAWAYA, BASSEL E · 2011 to 2015
$1.9M
Translational Rescue Mechanisms in EukaryotesR01GM114308 · NIGMS · ROWAN UNIVERSITY SCHOOL/OSTEOPATHIC MED · PI SHCHERBIK, NATALIA · 2016 to 2020
$1.6M
EGR-mediated STIM1-PMCA expression and function in T cell subsetsR01GM117907 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI SOBOLOFF, JONATHAN A · 2016 to 2019
$1.6M
REGULATION OF HIV-1 GENE TRANSCRIPTION IN CNSR01NS040673 · NINDS · TEMPLE UNIVERSITY · PI SAWAYA, BASSEL E · 2000 to 2004
$1.6M
Role of microRNA in HIV associated neurological disorder (HAND).R01MH093331 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI SAWAYA, BASSEL E · 2011 to 2013
$1.1M
NIAID NIH HHS R01 AI152506NIA NIH HHS R01 AG054411NIDA NIH HHS P50 DA026306NIGMS NIH HHS R01 GM114308NIGMS NIH HHS R01 GM117907NIMH NIH HHS R01 MH087332NIMH NIH HHS R01 MH093331NIMH NIH HHS R01 MH104131NIMH NIH HHS R01 MH105330NINDS NIH HHS R01 NS040673NINDS NIH HHS R01 NS076402
6 · The paper itself

Abstract

For over two decades, highly active antiretroviral therapy (HAART) was able to help prolong the life expectancy of people living with HIV-1 (PLWH) and eliminate the virus to an undetectable level. However, an increased prevalence of HIV- associated neurocognitive disorders (HAND) was observed. These symptoms range from neuronal dysfunction to cell death. Among the markers of neuronal deregulation, we cite the alteration of synaptic plasticity and neuronal communications. Clinically, these dysfunctions led to neurocognitive disorders such as learning alteration and loss of spatial memory, which promote premature brain aging even in HAART-treated patients. In support of these observations, we showed that the gp120 protein deregulates miR-499-5p and its downstream target, the calcineurin (CaN) protein. The gp120 protein also promotes the accumulation of calcium (Ca

Indexed as

HIV-1HIV InfectionsMicroRNAsBrainCalcineurinCell DeathHumansCalcineurinMicroRNAsCalcineurinFusion/FissionHIV-1 gp120Neurodegenerative disease

Identifiers

PMID36925028
PMCPMC10484070
OpenAlexW4324135430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.